evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

106 questions · 106 findings · 30 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 21 · 19.8%GRADE not reported 5 · 4.7%Very low 41 · 38.7%Low 16 · 15.1%Moderate 20 · 18.9%High 3 · 2.8%

Summary of findings: pioglitazone monotherapy vs no intervention

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy showed no clear difference in serious adverse events (N) compared with no intervention (low certainty).

1 finding from 1 review

Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly vs emicizumab 3.0 mg/kg every 2 weeks

Serious adverse events · people without inhibitors

Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly showed no clear difference in serious adverse events compared with emicizumab 3.0 mg/kg every 2 weeks (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Intraperitoneal local anaesthetic vs control

Serious adverse events · people undergoing laparoscopic cholecystectomy.

It is very uncertain whether summary of findings table ‐ Intraperitoneal local anaesthetic changes serious adverse events compared with control (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Platelet transfusion vs open control

All serious adverse events · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use

Summary of findings table ‐ Platelet transfusion showed no clear difference in all serious adverse events compared with open control (moderate certainty).

1 finding from 1 review

Summary of findings: bevacizumab vs ranibizumab

Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration

Summary of findings: bevacizumab showed no clear difference in serious systemic adverse events at 1 yearb compared with ranibizumab (moderate certainty).

1 finding from 1 review

Fecal microbiota transplantation vs control

Serious adverse events · adults with recurrent Clostridioides difficile infection (rCDI)

Summary of findings table ‐ Fecal microbiota transplantation (FMT) showed no clear difference in serious adverse events compared with control (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy

Serious adverse events · people without inhibitors

Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy

Serious adverse events · people without inhibitors

Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).

1 finding from 1 review

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo/open control

All serious adverse events · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in all serious adverse events compared with placebo/open control (high certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Serious adverse events ‐ total · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).

1 finding from 1 review